Aurobindo Pharma Ltd. - Research Center
524804 AUROPHARMA Group (A) BSE data
Results
Statement
More
| Mar ' 23 |
Mar ' 22 |
Mar ' 21 |
Mar ' 20 |
Mar ' 19 |
Equity share capital
| 58.59 |
58.59 |
58.59 |
58.59 |
58.59 |
Share application money
Preference share capital
Reserves & surplus
| 17,855.58 |
17,058.75 |
15,866.02 |
12,966.97 |
11,292.03 |
Secured loans
| 4,142.57 |
1,818.62 |
3,953.10 |
3,730.32 |
4,519.80 |
Unsecured loans
Total
| 22,056.74 |
18,935.96 |
19,877.71 |
16,755.88 |
15,870.42 |
Gross block
| 6,148.98 |
5,680.29 |
6,685.57 |
6,113.26 |
5,445.19 |
Less : revaluation reserve
Less : accumulated depreciation
| 2,461.48 |
2,094.46 |
2,213.50 |
1,748.57 |
1,295.49 |
Net block
| 3,687.50 |
3,585.83 |
4,472.07 |
4,364.69 |
4,149.70 |
Capital work-in-progress
| 239.09 |
225.15 |
734.89 |
726.62 |
789.01 |
Investments
| 8,221.78 |
6,584.36 |
5,009.93 |
2,519.70 |
2,339.06 |
Current assets, loans & advances
| 12,785.28 |
11,205.61 |
12,972.10 |
11,923.56 |
10,862.95 |
Less : current liabilities & provisions
| 2,876.91 |
2,664.99 |
3,311.28 |
2,778.69 |
2,270.30 |
Total net current assets
| 9,908.37 |
8,540.62 |
9,660.82 |
9,144.87 |
8,592.65 |
Miscellaneous expenses not written
Total
| 22,056.74 |
18,935.96 |
19,877.71 |
16,755.88 |
15,870.42 |
Book value of unquoted investments
| 8,221.77 |
6,584.35 |
4,909.89 |
2,519.68 |
2,339.04 |
Market value of quoted investments
| 0.01 |
0.01 |
100.04 |
0.02 |
0.02 |
Contingent liabilities
| 596.69 |
277.61 |
1,337.36 |
2,174.36 |
2,736.18 |
Number of equity sharesoutstanding (Lacs)
| 5859.39 |
5859.39 |
5859.39 |
5859.39 |
5859.16 |